Previous 10 | Next 10 |
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies PR Newswire Single and multiple doses of FPI-1966 demonstrated therapeutic efficacy in a preclinical bladder xenograft model [ ...
Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer PR Newswire HAMILTON , ON and BOSTON, Sept. 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on develo...
Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference PR Newswire HAMILTON , ON and BOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focus...
Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development PR Newswire HAMILTON , ON and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focu...
Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire HAMILTON , ON and BOSTON, Sept. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generatio...
B. Riley has initiated Fusion Pharmaceuticals (FUSN +3.5%) with a buy rating and a $17 price target (~102% upside). Analyst Justin Walsh highlights the company's platform technology supporting early-stage, next-generation radiopharmaceuticals. He notes the company's collaboration with AstraZe...
Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production Canada NewsWire Fusion and TRIUMF to collaborate to p...
Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update Canada NewsWire Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022 FPI-1966 advancing to clinic HAMILTON, O...
Fusion Pharmaceuticals to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference Canada NewsWire HAMILTON , ON and BOSTON, Aug. 5, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on deve...
Fusion Pharmaceuticals (FUSN) announces that the U.S. FDA has cleared the company's Investigational New Drug ((IND)) applications for FPI-1966 and imaging agent FPI-1967. Shares up more than 10% post market.FPI-1966 is a targeted alpha therapy ((TAT)) designed to use ...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...